Roche News | finanzen.ch

Roche Aktie VALOR 1203211 / ISIN CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

16.08.22	FDA accepts supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
15.08.22	Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2 (GlobeNewswire)
12.08.22	Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older (GlobeNewswire)
02.08.22	Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results (GlobeNewswire)
28.07.22	Roche to present scientific progress across Alzheimer’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting (GlobeNewswire)
22.07.22	CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss (GlobeNewswire)
21.07.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche: Wechsel im VR-Präsidium und in der Konzernleitung im Frühling 2023 (GlobeNewswire)
21.07.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023 (GlobeNewswire)
21.07.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022 (GlobeNewswire)
21.07.22	[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit guten Halbjahresergebnissen (GlobeNewswire)
19.07.22	Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease (GlobeNewswire)
18.07.22	Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus (GlobeNewswire)
14.07.22	Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer (GlobeNewswire)
14.07.22	New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration (GlobeNewswire)
11.07.22	New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A (GlobeNewswire)
06.07.22	FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
29.06.22	Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care (GlobeNewswire)
28.06.22	Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics (GlobeNewswire)
16.06.22	Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options (GlobeNewswire)
16.06.22	Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease (GlobeNewswire)
15.06.22	Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19 (GlobeNewswire)
10.06.22	Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting (GlobeNewswire)
09.06.22	U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib) (GlobeNewswire)
09.06.22	European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer (GlobeNewswire)
08.06.22	European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
31.05.22	FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA) (GlobeNewswire)
27.05.22	New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma (GlobeNewswire)
25.05.22	Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.05.22	Roche develops unique PCR tests to detect the monkeypox virus (GlobeNewswire)
25.05.22	Roche entwickelt einzigartige PCR-Tests zur Erkennung des Affenpockenvirus (GlobeNewswire)
24.05.22	Data at the 2022 ASCO Annual Meeting highlight Roche’s continued commitment to innovation in oncology and personalised healthcare (GlobeNewswire)
12.05.22	Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure (GlobeNewswire)
11.05.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer (GlobeNewswire)
10.05.22	Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028 (GlobeNewswire)
29.04.22	New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
25.04.22	[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum im ersten Quartal 2022 (GlobeNewswire)
22.04.22	CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer (GlobeNewswire)
22.04.22	CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
04.04.22	U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults (GlobeNewswire)
04.04.22	New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis (GlobeNewswire)
30.03.22	Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer (GlobeNewswire)
25.03.22	CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.03.22	Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting (GlobeNewswire)
23.03.22	Roche donates additional medicines and diagnostics for Ukraine (GlobeNewswire)
16.03.22	Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern (GlobeNewswire)
16.03.22	New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA) (GlobeNewswire)
15.03.22	Roche Generalversammlung 2022 (GlobeNewswire)
15.03.22	Roche Annual General Meeting 2022 (GlobeNewswire)
08.03.22	Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio (GlobeNewswire)
02.03.22	Roche announces donation of essential medicines to Ukraine (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer